Engineering an aglycosylated Fc variant for enhanced FcγRI engagement and pH-dependent human FcRn binding

Keyphrases

• PH Dependence 100%
• FcRI 100%
• Fc Variants 100%
• FcRn Binding 100%
• Human FcRn 100%
• Immune Effector Cells 66%
• Fcγ Receptor 66%
• Tumor Cells 33%
• High Affinity 33%
• Mammalian Cells 33%
• Infected Cells 33%
• Specific Binding 33%
• Binding Affinity 33%
• Screening Method 33%
• IgG Antibody 33%
• Clinical Application 33%
• Serum Stability 33%
• Trastuzumab 33%
• Combinatorial Library 33%
• Therapeutic Antibody 33%
• Homodimeric 33%
• Library Screening 33%
• Fc Domain 33%
• Small Molecule Drugs 33%
• High-throughput Flow Cytometry 33%
• Bacterial Display 33%
• Aglycosylated Antibody 33%
• Antibody Fc Region 33%

Immunology and Microbiology

• Effector Cell 100%
• Immunity 100%
• Fc Receptor 100%
• Immunology 100%
• Binding Affinity 50%
• Wild Type 50%
• Immunoglobulin G 50%
• Conformation 50%
• Screening 50%
• Trastuzumab 50%
• Therapeutic Antibodies 50%
• Combinatorial Library 50%

Biochemistry, Genetics and Molecular Biology

• Immunity 100%
• Fc Receptor 100%
• Wild Type 50%
• Conformation 50%
• Binding Affinity 50%
• Mammalian Cell 50%
• Small Molecule 50%
• Immunoglobulin G 50%
• Screening 50%
• Trastuzumab 50%
• Therapeutic Antibodies 50%
• Bacterial Display 50%
• Combinatorial Library 50%
• Flow Cytometry 50%